Breakthrough Brief is paused while we strengthen editorial review. Interest: info@medcelerator.com
medcelerator
Contact

← All treatment types

Treatment type

GLP-1

Glucagon-like peptide-1 (and dual GIP/GLP-1) medicines for diabetes, weight, and labelled organ-protection uses. Authorized is not funded.
All latest →
All countriesUnited StatesCanadaUnited KingdomJapanChinaAustraliaSwitzerlandEuropean UnionNewestPatient Stories
FDA ApprovedUnited States

New Heart-Protection Use for Mounjaro in Type 2 Diabetes

Mounjaro (tirzepatide) — weekly shot for adults with type 2 diabetes that now also carries a labelled heart-protection use

FDA supplemental approval effective 27 August 2026 for a new use of Mounjaro (tirzepatide) injection — a once-weekly subcutaneous dual GIP/GLP-1 receptor…

This is for adults with type 2 diabetes who are at high risk for heart attack, stroke, or cardiovascular death, and who may already be candidates for weekly…

FDA ApprovedUnited StatesCanadaUnited Kingdom

New Daily Pill for Chronic Weight Management in Adults

Foundayo (orforglipron) for chronic weight management

FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight management and type 2 diabetes — those lines stay separate.